CRSP — CRISPR Therapeutics AG
Sector: Healthcare | Exchange: NASDAQ | Updated: 2026-04-08
CRISPR Therapeutics is a gene editing company focused on transformative gene-based medicines using CRISPR/Cas9. Its lead product Casgevy is the world’s first CRISPR-based therapy approved by the FDA.
Roadmap
Delivery: 0/13 (0%)
| Commitment | Date Said | Source | Follow-up | |
|---|---|---|---|---|
| ⏳ | Continue to advance zugocabtagene geleucel (zugo-cel) in ongoing Phase 1/2 clinical trial for relapsed or refractory B-cell malignancies | FY2025 10-K | ||
| ⏳ | Continue to advance CTX213, a deviceless beta cell replacement product candidate for Type 1 diabetes, through preclinical studies | FY2025 10-K | ||
| ⏳ | Advance CTX321 (targeting LPA for elevated lipoprotein(a)) through IND-enabling studies | FY2025 10-K | ||
| ⏳ | Continue to advance in vivo hematopoietic stem cell editing approaches for hemoglobinopathies using lipid nanoparticle-mediated delivery through preclinical studies | FY2025 10-K | ||
| ⏳ | Continue to advance internally developed targeted conditioning program for hemoglobinopathies through preclinical studies | FY2025 10-K | ||
| ⏳ | Evaluate zugocabtagene geleucel together with pirtobrutinib in aggressive B-cell lymphomas through collaboration with Eli Lilly | FY2025 10-K | ||
| ⏳ | Co-develop and co-commercialize CTX611 with Sirius Therapeutics under the Sirius Agreement | FY2025 10-K | ||
| ⏳ | Advance CTX340 (targeting angiotensinogen for refractory hypertension) through IND-enabling studies | FY2025 10-K | ||
| ⏳ | Advance CTX310 into Phase 1b clinical trials, prioritizing development in severe hypertriglyceridemia and refractory hypercholesterolemia | FY2025 10-K | ||
| ⏳ | Continue long-term follow-up clinical trials for CASGEVY designed to follow participants for up to 15 years after infusion | FY2025 10-K | ||
| ⏳ | Continue to advance zugocabtagene geleucel (zugo-cel) in ongoing clinical trials for autoimmune diseases (SLE, systemic sclerosis, inflammatory myositis, immune thrombocytopenia purpura, warm autoimmune hemolytic anemia) | FY2025 10-K | ||
| ⏳ | Advance CTX460 (targeting SERPINA1 for alpha-1 antitrypsin deficiency using SyNTase editing platform) through preclinical studies | FY2025 10-K | ||
| ⏳ | Continue investigation of CTX611 in ongoing Phase 2 clinical trial for preventing venous thromboembolism in patients undergoing total knee arthroplasty | FY2025 10-K |
Management Quotes
“In TDT, 98.2% of patients (55/56) achieved TI12 in either CLIMB-111 or CLIMB-131.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“In SCD, 100% of patients (45/45) achieved VF12 in either CLIMB-121 or the long-term follow-up study CLIMB-131.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#risk
“We have partnered with Vertex Pharmaceuticals Incorporated for the development and commercialization of CASGEVY. Vertex has significant control over the CASGEVY program.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#risk
“We aim to transform the treatment paradigm for cardiovascular disease by developing one-time in vivo editing therapies targeting ANGPTL3 and PCSK9.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“Efficacy data presented to date support the profile of CASGEVY as a potential one-time functional cure for patients with severe sickle cell disease and transfusion-dependent beta thalassemia.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“Zugo-cel continues to advance in both autoimmune disease and hematologic malignancies.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and regenerative medicine.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“CASGEVY has been approved in the United States, European Union, Great Britain, Canada, Switzerland, Kingdom of Saudi Arabia, and Bahrain.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
“CTX310 is currently being investigated in an ongoing Phase 1b clinical trial targeting ANGPTL3 for the treatment of hyperlipidemia.”
— CRISPR Therapeutics Management, FY2025 10-K (2026-02-12)
#strategy
Analysis Notes
FY2025 10-K Analysis (2026-04-04)
Rating: ⭐⭐⭐
Tags: strategy
Financial Performance
Pre-profitability biotech. FY2025 revenue $3.5M (milestone-based, no major milestones). Cash burn $345.9M. Cash & investments $1.98B. R&D $265.3M (down from $320.7M). Net loss $581.6M ($6.47/share). Key milestone: CTX310 Phase 1b data published in NEJM. Pediatric CASGEVY data positive at ASH.
Management Tone
Bullish
FY2025 vs FY2024 — Narrative Evolution Analysis (2026-04-04)
Rating: ⭐⭐⭐
Tags: strategy
Narrative Drift
Evolved from gene editing pioneer to broader biopharmaceutical company. Expanded beyond CRISPR/Cas9 to include siRNA (Sirius partnership) and SyNTase technologies. Added Eli Lilly collaboration for zugocabtagene geleucel.
Red Flags
- CTX131 CD70 program no longer emphasized
- Expanded macroeconomic risk factors (inflation, tariffs, geopolitical tensions)
- Type 1 diabetes folded into regenerative medicine franchise
Financials
Data available for: 2022, 2023, 2024, 2025 (USD Million)
- 10-K FY2022 (filed 2023-02-21)
- 10-K FY2023 (filed 2024-02-21)
- 10-K FY2024 (filed 2025-02-11)
- 10-K FY2025 (filed 2026-02-12)